Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Ohshaw who wrote (1342)	11/2/1999 9:04:00 AM
From: out_of_the_loop	Read Replies (2) \| Respond to of 5582

People in both groups would have had no prior experience with Zicam, first of all, and should not have had any preconceived notions about what to feel. This study was done before the product was released and before the product even had a name. More importantly, the people in a double-blinded study simply have no idea which they are getting. The placebo contained everything except the zinc gluconate from what I could tell. Finally, the study will likely contain a comparison of "side effects", reactions (no, I do not know this for a fact, but most studies do) that should include what you mentioned. If those side effects are nil from both groups, there is no difference anyway. At this point, you are assuming it is the zinc, rather than the matrix, that is causing this sensation but you really have no way to be certain of that. I do not see how this could honestly be an issue in a double-blinded study.